Cargando…

Do biological disease-modifying antirheumatic drugs reduce the spinal fracture risk related to ankylosing spondylitis? A longitudinal multiregistry matched cohort study

OBJECTIVES: Ankylosing spondylitis (AS) is associated with an increased spinal fracture risk due to the loss of elasticity in spinal motion segments. With the introduction of biological disease-modifying antirheumatic drug (bDMARD) treatment for AS, the individual course of the disease has been amel...

Descripción completa

Detalles Bibliográficos
Autores principales: Robinson, Yohan, Olerud, Claes, Willander, Johan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5770921/
https://www.ncbi.nlm.nih.gov/pubmed/29288176
http://dx.doi.org/10.1136/bmjopen-2017-016548